Cheryl A. Pickett

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

Josep Malvehy, Igor Samoylenko, Dirk Schadendorf et al. · Journal for ImmunoTherapy of Cancer · 2021 · 79 citations · Full text

Medicine, Immunology, Oncology +17

[11C]Metahydroxyephedrine and [18F]Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma

Gary N. Mann, Jeanne M. Link, Pam Pham et al. · Annals of Surgical Oncology · 2006 · 72 citations

Medicine, Endocrinology, Neurology +8

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis et al. · EBioMedicine · 2019 · 68 citations · Full text

Life Sciences, Immunology, Oncology +16

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Véronique Dièras, Hans Wildiers, Jacek Jassem et al. · The Breast · 2015 · 50 citations · Full text

Medicine, Oncology, Pharmacology +16